CSF2 and melanoma: Recently, an intratumoral therapy with talimogene laherparepvec (T-VEC), an attenuated herpes simplex virus, type 1 (HSV-1) engineered to express human granulocyte-macrophage colony-stimulating factor (GM-CSF), has been approved to treat patients with melanoma.